Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

Exclusion Criteria

• •Previously diagnosed with glaucoma in either eye.
• •The time planned for study drug administration is more than 120 hours from the onset of the symptoms.
• •History of chronic angle-closure in either eye.
• •Secondary angle-closure/secondary angle-closure glaucoma in the study eye.
• •Monocular subjects.
• •Prior incisional intraocular surgery.
• •Inability to perform a reliable visual field test on Day 0 in the study eye.
• •History of panretinal photocoagulation or macular laser photocoagulation in the study eye.
• •History of active malignancy within the last 5 years (however, non facial, basal cell carcinoma is allowed).
• •History of myocardial infarction within the last 6 months.
• •Received any drugs known to cause optic nerve or retinal toxicity within 14 days prior to dosing.
• •Women who are pregnant or lactating.
• •Participating in a concurrent interventional study with the last intervention occurring within 30 days prior to planned dosing with QPI-1007.